Back Hepatitis B

Hepatitis B

FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data

The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax Technologies' experimental hepatitis B virus (HBV) vaccine candidate with a toll-like receptor 9 adjuvant, stating it wants to see further data on safety in adults including seniors, the company announced this week.

alt

Read more:

Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver

N-acetylcysteine (NAC) administered during recovery of a liver from a deceased donor can help reduce damage during transplantation and increase survival of the liver graft in the recipient, according to a study published in the February 19, 2013, issue of Liver Transplantation.

alt

Read more:

Heavy Alcohol Use Increases Liver Cancer Risk for People with Hepatitis B

Hepatitis B patients with liver cirrhosis who consumed large amounts of alcohol were more likely to develop hepatocellular carcinoma (HCC) than people who drank less, according to a report in the December 6, 2012, online edition of the Journal of Hepatology. However, antiviral treatment can help prevent liver cancer.

alt

 

Read more:

Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection

The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).

alt

Read more:

Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B

Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.

alt

Read more:

HIV+ Less Likely to Respond to Hepatitis B Vaccine, but More Shots Increase Protection

Adults in Kenya responded as well overall to hepatitis B vaccination as people in high-income countries. People with HIV had poorer response, but this could be mostly overcome with repeated doses, according to a study described in the February 1, 2013, Journal of Infectious Diseases.

alt

Read more:

Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity

Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.

alt

Read more:

Chronic Hepatitis Cohort Study Sheds Light on Burden of Hepatitis B and C in U.S.

People born between 1945 and 1964 account for the highest proportion of hepatitis B and C cases, and these viruses are a significant cause of illness and death, according to an analysis described in the January 1, 2013, Clinical Infectious Diseases.

alt

Read more:

Researchers Discover Structure of Hepatitis B Antigen that Interferes with Immune Response

Researchers from the University of Oxford and the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases have determined the crystal structure of the hepatitis B "e" antigen (HBeAg), which plays a role in immune tolerance and chronic hepatitis B virus (HBV) infection, according to a study published in the January 8, 2013, issue of the journal Structure. These findings may aid the development of new therapies that improve immune response against the virus.

alt

Read more: